Inclusion Criteria:

          -  Subjects must have histologically confirmed, locally advanced or metastatic solid
             cancers of the following histological types:

               1. predominantly epithelial (≥50% tumor component) pleural or peritoneal
                  mesothelioma

               2. epithelial ovarian cancer (fallopian tube and primary peritoneal cancers are
                  eligible)

               3. adenocarcinoma of the pancreas,

               4. triple-negative adenocarcinoma of the breast

               5. non-small-cell adenocarcinoma of the lung

               6. gastric cancer (including gastro-esophageal junction)

               7. colon cancer

               8. cholangiocarcinoma

               9. Thymic carcinoma

          -  Subjects must have no standard therapy available, or have actively refused standard
             therapy

          -  Subjects must provide samples of archival tumor tissue collected and submitted anytime
             during the study

          -  Subjects must have a life expectancy of at least 12 weeks

          -  Subjects must have ECOG (Eastern Cooperative Oncology Group) performance status of 0
             or 1

          -  Subjects must have adequate bone marrow, renal and hepatic function and coagulation

          -  Subjects must have normal or clinically insignificant ECG at screening

          -  Women of reproductive potential must have a negative serum pregnancy test obtained
             within 3 days before the start of anetumab ravtansine

          -  Women of childbearing potential and fertile men must agree to use adequate
             contraception when sexually active. This applies from the time period between signing
             of the informed consent until at least 6 months after the last administration of the
             last study drug. Male patients with a female partner of childbearing potential must
             use a condom and ensure that an additional form of contraception is also used during
             treatment and until 6 months after last study drug administration.

        Exclusion Criteria:

          -  Previous or concurrent cancer that is distinct in primary site or histology from the
             cancer being evaluated in this study, except cervical carcinoma in situ, treated basal
             cell carcinoma, superficial noninvasive bladder tumors or any previous cancer
             curatively treated ≥ 3 years before the start of anetumab ravtansine

          -  New or progressive brain or meningeal or spinal metastases

          -  Corneal epitheliopathy or any eye disorder that may predispose the subjects to
             drug-induced corneal epitheliopathy, or may interfere with diagnosis of
             treatment-emergent corneal epitheliopathy at the ophthalmologist's or the
             investigator's discretion

          -  History or current evidence of

               -  biliary cirrhosis

               -  malignant biliary obstruction unless the bile flow to the gastrointestinal tract
                  is maintained by a fully operational biliary stent

               -  CTCAE (Common Terminology Criteria for Adverse Events) Grade ≥2 bleeding disorder
                  within 4 weeks before the start of anetumab ravtansine

               -  uncontrolled cardiovascular disease or uncontrolled hypertension

               -  Long QT Syndrome

               -  HIV infection

               -  Hepatitis B or C infection

          -  Had a major surgery or significant trauma within 4 weeks before the start of anetumab
             ravtansine

          -  Had solid organ or bone marrow transplantation

          -  Have LVEF (left ventricular ejection fraction) <50% at screening

          -  Have QTc >450 ms or heart rate ≥100 bpm or ≤45 bpm at screening

          -  Poor CYP2D6 metabolizers based on the screening test for genetic polymorphisms in
             CYP2D6 metabolizing capacity